The expression levels of EBP50 decreased with the increase in pathological stage or T classification of extrahepatic bile duct carcinoma. The normal and extrahepatic bile duct carcinoma tissues underwent an IHC reaction with anti-EBP50 antibodies. The variation in EBP50 expression levels among (A) pathological stage, (B) T classification and (C) N classification was examined using analysis of variance, P=0.1069 between N0 and N1/2. **P=0.0016 between normal, stage I/II and stage III/IV, *P=0.0136 among T1, T2 and T3/4 EBP50, ezrin-radixin-moesin-binding phosphoprotein-50; IHC, immunohistochemistry; T, tumor; N, node.